http://orcid.org/0000-0003-0841-004X
References
- Koran LM, Hanna GL, Hollander E, et al. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(Suppl 7):5–53.
- Ahmari SE, Spellman T, Douglass NL, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013;340(6137):1234–1239. doi: 10.1126/science.1234733
- Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol Psychiatry. 2010;15(1):53–63. doi: 10.1038/mp.2008.94
- Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132(3):314–332. doi: 10.1016/j.pharmthera.2011.09.006
- Radvansky BM, Puri S, Sifonios AN, et al. Ketamine-A narrative review of its uses in medicine. Am J Ther. 2016;23(6):e1414–e1426. doi: 10.1097/MJT.0000000000000257
- Morris RG, Anderson E, Lynch GS, et al. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986;319(6056):774–776. doi: 10.1038/319774a0
- Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73(12):1133–1141. doi: 10.1016/j.biopsych.2013.03.026
- Rodriguez CI, Kegeles LS, Flood P, et al. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(4):567–569. doi: 10.4088/JCP.10l06653
- Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72(11):964–970. doi: 10.1016/j.biopsych.2012.05.028
- Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475–2483. doi: 10.1038/npp.2013.150
- Rodriguez CI, Lapidus KAB, Zwerling J, et al. Challenges in testing intranasal ketamine in obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(4):466–467. doi: 10.4088/JCP.16cr11234
- Rodriguez CI, Zwerling J, Kalanthroff E, et al. Effect of a novel NMDA receptor modulator, rapastinel (formerly GLYX-13), in OCD: proof of concept. Am J Psychiatry. 2016;173(12):1239–1241. doi: 10.1176/appi.ajp.2016.16080868
- Goodman WK, Price LH, Woods SW. Pharmacologic challenges in obsessive-compulsive disorder. In: Zohar J, Insel T, Rasmussen SA, editors The psychobiology of obsessive-compulsive disorder. New York (NY): Springer; 1991. p. 162–186.